Follow
Klaus H. Metzeler
Klaus H. Metzeler
University Hospital Leipzig, Germany
Verified email at klaus-metzeler.de - Homepage
Title
Cited by
Cited by
Year
Stem cell gene expression programs influence clinical outcome in human leukemia
K Eppert, K Takenaka, ER Lechman, L Waldron, B Nilsson, P Van Galen, ...
Nature medicine 17 (9), 1086-1093, 2011
11512011
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
G Marcucci, K Maharry, YZ Wu, MD Radmacher, K Mrózek, D Margeson, ...
Journal of clinical oncology 28 (14), 2348, 2010
9472010
A 17-gene stemness score for rapid determination of risk in acute leukaemia
SWK Ng, A Mitchell, JA Kennedy, WC Chen, J McLeod, N Ibrahimova, ...
Nature 540 (7633), 433-437, 2016
7542016
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
KH Metzeler, T Herold, M Rothenberg-Thurley, S Amler, MC Sauerland, ...
Blood, The Journal of the American Society of Hematology 128 (5), 686-698, 2016
5662016
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia
K Mrózek, G Marcucci, D Nicolet, KS Maharry, H Becker, SP Whitman, ...
Journal of clinical oncology 30 (36), 4515, 2012
5232012
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia
KH Metzeler, M Hummel, CD Bloomfield, K Spiekermann, J Braess, ...
Blood 112 (10), 4193-4201, 2008
4432008
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study
KH Metzeler, K Maharry, MD Radmacher, K Mrózek, D Margeson, ...
Journal of clinical oncology 29 (10), 1373, 2011
4262011
Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical …
A Dufour, F Schneider, KH Metzeler, E Hoster, S Schneider, E Zellmeier, ...
Journal of clinical oncology 28 (4), 570-577, 2010
3782010
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
KH Metzeler, H Becker, K Maharry, MD Radmacher, J Kohlschmidt, ...
Blood, The Journal of the American Society of Hematology 118 (26), 6920-6929, 2011
3462011
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia
G Marcucci, KH Metzeler, S Schwind, H Becker, K Maharry, K Mrózek, ...
Journal of clinical oncology 30 (7), 742, 2012
3422012
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression …
JH Mendler, K Maharry, MD Radmacher, K Mrózek, H Becker, ...
Journal of clinical oncology 30 (25), 3109, 2012
3332012
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with …
SP Whitman, K Maharry, MD Radmacher, H Becker, K Mrózek, ...
Blood, The Journal of the American Society of Hematology 116 (18), 3622-3626, 2010
2662010
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
C Krupka, P Kufer, R Kischel, G Zugmaier, FS Lichtenegger, T Köhnke, ...
Leukemia 30 (2), 484-491, 2016
2572016
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
S Haubner, F Perna, T Köhnke, C Schmidt, S Berman, C Augsberger, ...
Leukemia 33 (1), 64-74, 2019
2522019
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
KH Metzeler, A Walker, S Geyer, R Garzon, RB Klisovic, CD Bloomfield, ...
Leukemia 26 (5), 1106-1107, 2012
2422012
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
S Schwind, K Maharry, MD Radmacher, K Mrózek, KB Holland, ...
Journal of clinical oncology 28 (36), 5257, 2010
2282010
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330
C Krupka, P Kufer, R Kischel, G Zugmaier, J Bögeholz, T Köhnke, ...
Blood, The Journal of the American Society of Hematology 123 (3), 356-365, 2014
2242014
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients
G Marcucci, KS Maharry, KH Metzeler, S Volinia, YZ Wu, K Mrózek, ...
Journal of clinical oncology 31 (17), 2086, 2013
2152013
Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
T Herold, M Rothenberg-Thurley, VV Grunwald, H Janke, D Goerlich, ...
Leukemia 34 (12), 3161-3172, 2020
1882020
Adults with Philadelphia chromosome–like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis
T Herold, S Schneider, KH Metzeler, M Neumann, L Hartmann, ...
haematologica 102 (1), 130, 2017
1712017
The system can't perform the operation now. Try again later.
Articles 1–20